The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), is pleased to ...

A former employee of Stanford University was found guilty of accessing a clinical research database for a multisite breast ...

Shortly after he became CEO of Bayer AG in 2023, CEO Bill Anderson began waging war against bureaucracy to make the life ...

Naheed Mangi, a former Stanford coordinator, was found guilty of tampering with a breast cancer study database.

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Marya Lieberman is a chemistry professor whose NIH-funded project is focused on developing a tool to detect poor-quality ...

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...